F

Fennec Pharmaceuticals Inc
TSX:FRX

Watchlist Manager
Fennec Pharmaceuticals Inc
TSX:FRX
Watchlist
Price: 10.77 CAD Market Closed
Market Cap: 294.3m CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one FRX stock under the Base Case scenario is 19.79 CAD. Compared to the current market price of 10.77 CAD, Fennec Pharmaceuticals Inc is Undervalued by 46%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FRX Relative Value
Base Case
19.79 CAD
Undervaluation 46%
Relative Value
Price
F
Worst Case
Base Case
Best Case

Valuation Multiples

7.2
P/S
P/S
Price to Sales
7.2
vs History
44
vs Industry
67
Median 3Y
5.4
Median 5Y
5.4
Industry
7
Forward
4.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
3
Median 3Y
-10.3
Median 5Y
-10.3
Industry
22.7
Forward
51.2
More Details
8.2
P/OCF
P/OCF
Price to OCF
8.2
vs History
4
vs Industry
14
Median 3Y
-10.4
Median 5Y
-11
Industry
19.4
More Details
18.1
P/FCFE
P/FCFE
Price to FCFE
18.1
vs History
11
vs Industry
12
Median 3Y
5.8
Median 5Y
-10.9
Industry
22.6
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
1
Median 3Y
-24.1
Median 5Y
5.7
Industry
2.6
More Details
6.6
EV/S
EV/S
Enterprise Value to Sales
6.6
vs History
44
vs Industry
58
Median 3Y
5
Median 5Y
5
Industry
7.3
Forward
4.3
More Details
7.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.4
vs History
25
vs Industry
61
Median 3Y
5.2
Median 5Y
0
Industry
9.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
2
Median 3Y
-9.9
Median 5Y
-9.1
Industry
4.6
Forward
17.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
2
Median 3Y
-9.9
Median 5Y
-9.1
Industry
4.5
Forward
102.4
More Details
7.6
EV/OCF
EV/OCF
Enterprise Value to OCF
7.6
vs History
4
vs Industry
14
Median 3Y
-10.5
Median 5Y
-10.5
Industry
5
More Details
7.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
7.6
vs History
4
vs Industry
11
Median 3Y
-10.5
Median 5Y
-10.5
Industry
3.7
More Details
13.6
EV/IC
EV/IC
Enterprise Value to IC
13.6
vs History
42
vs Industry
18
Median 3Y
12.7
Median 5Y
11
Industry
4.9
More Details

Multiples Across Competitors

FRX Competitors Multiples
Fennec Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Fennec Pharmaceuticals Inc
TSX:FRX
213.6m CAD 7.2 -15.4 -17.1 -17.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 524 117.8 -164 088 -199 255.2 -196 981.4
US
Abbvie Inc
NYSE:ABBV
324.6B USD 5.7 78.1 14.9 22.1
US
Amgen Inc
NASDAQ:AMGN
146.5B USD 4.3 24.7 13.5 22.3
US
Gilead Sciences Inc
NASDAQ:GILD
131.7B USD 4.6 22.1 9.6 13.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114B USD 10.3 -115.3 24.5 25.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 040.6 -520.7 -567 -551.9
AU
CSL Ltd
ASX:CSL
116.6B AUD 4.9 27.4 16.9 21.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.4B USD 3.9 12.3 10.9 12.2
US
Seagen Inc
F:SGT
39.3B EUR 19.7 -60.3 -64.9 -58.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41B USD 17.5 -151.9 -681 -341.3
P/E Multiple
Earnings Growth PEG
US
F
Fennec Pharmaceuticals Inc
TSX:FRX
Average P/E: 32.9
Negative Multiple: -15.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -164 088 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.1
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -115.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.7 N/A N/A
AU
CSL Ltd
ASX:CSL
27.4
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -151.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
F
Fennec Pharmaceuticals Inc
TSX:FRX
Average EV/EBITDA: 15.1
Negative Multiple: -17.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 255.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.6
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -567 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -681 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
F
Fennec Pharmaceuticals Inc
TSX:FRX
Average EV/EBIT: 19.4
Negative Multiple: -17.1
158%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 981.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.1
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.6
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -551.9 N/A N/A
AU
CSL Ltd
ASX:CSL
21.2
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -341.3 N/A N/A

See Also

Summary
FRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
FRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FRX stock valuation using valuation multiples.
Wall Street Estimates
FRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 263,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.